Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To compare the safety and efficacy of erythropoietin and roxadustat in the treatment of anemia in chronic kidney disease (CKD) patients during the peridialysis period, providing a reference for clinical practice
This multicenter retrospective study collected clinical data from 40,324 patients with stage 5 CKD and anemia treated with either 10,000 IU erythropoietin or roxadustat between January 1, 2015, and December 31, 2021, across 82 hospitals (42 tertiary hospitals and 40 secondary hospitals). Patients were divided into an erythropoietin group and a roxadustat group based on their treatment regimen. Propensity score matching (PSM) was used for 1:4 matching, resulting in 545 patients in the roxadustat group and 1,804 patients in the erythropoietin group. Baseline characteristics, incidence of cardiovascular and cerebrovascular events, thrombotic events, major adverse cardiovascular events (MACE+), number of hospitalizations due to complications, and length of hospital stay were compared between the two groups. Medication dosage and changes in hemoglobin (Hb) levels (compared to baseline) were recorded for three months after treatment initiation
After PSM, there were no statistically significant differences in baseline characteristics between the two groups (P>0.05). Within the first six months and one year of initial treatment and during the first three months post-dialysis, the roxadustat group had higher rates of cardiovascular and cerebrovascular events, MACE+, and hospitalization for complications compared to the erythropoietin group (P<0.001). However, no significant differences were observed between the groups in these outcomes during the one-year follow-up after the peri-dialysis period (P>0.05). Hb changes in the first month of treatment were greater in the erythropoietin group than in the roxadustat group (P<0.001), but lower in the second month (P=0.005), with no significant difference by the third month (P=0.331). A higher proportion of patients in the erythropoietin group maintained Hb levels within the target range after three months of continuous treatment (P=0.021).
For anemia in stage 5 CKD patients during the peridialysis period, erythropoietin demonstrated superior cardiovascular safety compared to roxadustat and was more effective in improving Hb levels in the short term
